Decoding anemoside B4: Core mechanistic axes and an omics-to-atom paradigm.

Area of Science:

• Pharmacology
• Molecular Biology
• Immunology

Background:

• Anemoside B4 (AB4), a triterpenoid saponin from Pulsatilla chinensis, is in clinical trials for ulcerative colitis.
• AB4 exhibits broad efficacy in inflammatory, oncological, viral, and metabolic conditions, but its molecular mechanisms are not fully understood.

Purpose of the Study:

• To elucidate the pleiotropic molecular mechanisms of Anemoside B4.
• To address the "context-dependency paradox" of AB4's pathway regulation.
• To propose a novel "Omics-to-Atom" paradigm for natural product pharmacology.

Main Methods:

• Integration of single-cell/spatial transcriptomics, cell-type-specific chemoproteomics, and cryo-electron microscopy (Cryo-EM).
• Utilizing CRISPR-based functional genomics to dissect cellular heterogeneity.
• Analysis of upstream pattern-recognition receptor (PRR) sensing, cell-fate control, immunometabolic coupling, and innate immune amplification.

Main Results:

• AB4's actions were distilled into four mechanistic axes: PRR sensing, cell-fate control, immunometabolic coupling, and antiviral immune amplification.
• A "context-dependency paradox" was identified, with AB4 suppressing the PI3K/Akt pathway in cancer but activating it in diabetic muscle.
• Traditional bulk-tissue analyses were found to mask cell-type-specific drug-protein interactions.

Conclusions:

• The "Omics-to-Atom" paradigm reveals dynamic, context-specific drug-protein assemblies by dissecting cellular heterogeneity.
• This approach clarifies AB4's mechanism for patient stratification and safety prediction.
• The proposed paradigm offers a blueprint for advancing natural product pharmacology into precision medicine.